{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T11:51:48Z","timestamp":1789213908790,"version":"build-2803163510"},"reference-count":38,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,6,7]],"date-time":"2024-06-07T00:00:00Z","timestamp":1717718400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100018931","name":"AIO-Studien","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100018931","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["esmoopen.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["ESMO Open"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1016\/j.esmoop.2024.103628","type":"journal-article","created":{"date-parts":[[2024,7,13]],"date-time":"2024-07-13T07:49:29Z","timestamp":1720856969000},"page":"103628","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Dermatology-related quality-of-life outcomes in patients with RAS wild-type metastatic colorectal cancer treated with fluorouracil and folinic acid with or without panitumumab (Pmab) maintenance after FOLFOX\u00a0+ Pmab induction: a prespecified secondary analysis of the phase II randomized PanaMa (AIO KRK 0212) trial"],"prefix":"10.1016","volume":"9","author":[{"given":"A.","family":"Ballhausen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Karthaus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Fruehauf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"U.","family":"Graeven","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"M\u00fcller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.O.","family":"K\u00f6nig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.F.","family":"von Weikersthal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Sommerh\u00e4user","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Jelas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.H.S.","family":"Alig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Kurreck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Stahler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Goekkurt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Held","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Kasper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Heinrich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Heinemann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Stintzing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Trarbach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.P.","family":"Modest","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.esmoop.2024.103628_bib1","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.annonc.2022.10.003","article-title":"Metastatic colorectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"34","author":"Cervantes","year":"2023","journal-title":"Ann Oncol"},{"issue":"8","key":"10.1016\/j.esmoop.2024.103628_bib2","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1093\/annonc\/mdx175","article-title":"Prognostic and predictive value of primary tumour side in patients with RAS wild-type metastatic colorectal cancer treated with chemotherapy and EGFR directed antibodies in six randomized trials","volume":"28","author":"Arnold","year":"2017","journal-title":"Ann Oncol"},{"issue":"12","key":"10.1016\/j.esmoop.2024.103628_bib3","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1016\/S1470-2045(20)30527-1","article-title":"Effect of duration of adjuvant chemotherapy for patients with stage III colon cancer (IDEA collaboration): final results from a prospective, pooled analysis of six randomised, phase 3 trials","volume":"21","author":"Andre","year":"2020","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.esmoop.2024.103628_bib4","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1093\/annonc\/mdl336","article-title":"Phase II study of an optimized 5-fluorouracil-oxaliplatin strategy (OPTIMOX2) with celecoxib in metastatic colorectal cancer: a GERCOR study","volume":"18","author":"Andre","year":"2007","journal-title":"Ann Oncol"},{"issue":"12","key":"10.1016\/j.esmoop.2024.103628_bib5","doi-asserted-by":"crossref","first-page":"2203","DOI":"10.1093\/annonc\/mdw425","article-title":"Quality of life assessment in patients with metastatic colorectal cancer receiving maintenance therapy after first-line induction treatment: a preplanned analysis of the phase III AIO KRK 0207 trial","volume":"27","author":"Quidde","year":"2016","journal-title":"Ann Oncol"},{"issue":"3","key":"10.1016\/j.esmoop.2024.103628_bib6","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1200\/JCO.2005.03.0106","article-title":"OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-Go fashion in advanced colorectal cancer - a GERCOR study","volume":"24","author":"Tournigand","year":"2006","journal-title":"J\u00a0Clin Oncol"},{"issue":"9","key":"10.1016\/j.esmoop.2024.103628_bib7","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1001\/jamaoncol.2019.1467","article-title":"Maintenance therapy with panitumumab alone vs panitumumab plus fluorouracil-leucovorin in patients with RAS wild-type metastatic colorectal cancer: a phase 2 randomized clinical trial","volume":"5","author":"Pietrantonio","year":"2019","journal-title":"JAMA Oncol"},{"issue":"9","key":"10.1016\/j.esmoop.2024.103628_bib8","doi-asserted-by":"crossref","first-page":"2128","DOI":"10.1093\/annonc\/mdx322","article-title":"Maintenance treatment with capecitabine and bevacizumab versus observation in metastatic colorectal cancer: updated results and molecular subgroup analyses of the phase 3 CAIRO3 study","volume":"28","author":"Goey","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.esmoop.2024.103628_bib9","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2023.112945","article-title":"Optimal maintenance strategy following FOLFOX plus anti-EGFR induction therapy in patients with RAS wild type metastatic colorectal cancer: an individual patient data pooled analysis of randomised clinical trials","volume":"190","author":"Raimondi","year":"2023","journal-title":"Eur J Cancer"},{"issue":"1","key":"10.1016\/j.esmoop.2024.103628_bib10","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1200\/JCO.21.01332","article-title":"Panitumumab plus fluorouracil and folinic acid versus fluorouracil and folinic acid alone as maintenance therapy in RAS wild-type metastatic colorectal cancer: the randomized PANAMA trial (AIO KRK 0212)","volume":"40","author":"Modest","year":"2022","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.esmoop.2024.103628_bib11","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.ejca.2020.04.048","article-title":"Health-related quality of life in patients with RAS wild-type metastatic colorectal cancer treated with panitumumab-based first-line treatment strategy: a pre-specified secondary analysis of the Valentino study","volume":"135","author":"Raimondi","year":"2020","journal-title":"Eur J Cancer"},{"issue":"11","key":"10.1016\/j.esmoop.2024.103628_bib12","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.1016\/j.clinthera.2017.09.015","article-title":"Moving beyond conventional clinical trial end points in treatment-refractory metastatic colorectal cancer: a composite quality-of-life and symptom control end point","volume":"39","author":"Gong","year":"2017","journal-title":"Clin Ther"},{"issue":"3","key":"10.1016\/j.esmoop.2024.103628_bib13","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1093\/annonc\/mdw617","article-title":"Does severe toxicity affect global quality of life in patients with metastatic colorectal cancer during palliative systemic treatment? A systematic review","volume":"28","author":"Schuurhuizen","year":"2017","journal-title":"Ann Oncol"},{"issue":"2","key":"10.1016\/j.esmoop.2024.103628_bib14","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.ejca.2004.10.017","article-title":"Analysis and interpretation of health-related quality-of-life data from clinical trials: basic approach of The National Cancer Institute of Canada Clinical Trials Group","volume":"41","author":"Osoba","year":"2005","journal-title":"Eur J Cancer"},{"issue":"5","key":"10.1016\/j.esmoop.2024.103628_bib15","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1093\/jnci\/85.5.365","article-title":"The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology","volume":"85","author":"Aaronson","year":"1993","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.esmoop.2024.103628_bib16","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2023.112955","article-title":"Health-related quality of life in patients with RAS wild-type metastatic colorectal cancer treated with fluorouracil and folinic acid with or without panitumumab as maintenance therapy: a prespecified secondary analysis of the PanaMa (AIO KRK 0212) trial","volume":"190","author":"Ballhausen","year":"2023","journal-title":"Eur J Cancer"},{"issue":"4","key":"10.1016\/j.esmoop.2024.103628_bib17","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1007\/s00520-012-1623-4","article-title":"The development of a Functional Assessment of Cancer Therapy (FACT) questionnaire to assess dermatologic symptoms associated with epidermal growth factor receptor inhibitors (FACT-EGFRI-18)","volume":"21","author":"Wagner","year":"2013","journal-title":"Support Care Cancer"},{"issue":"1","key":"10.1016\/j.esmoop.2024.103628_bib18","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1186\/s41687-020-00220-x","article-title":"A\u00a0prospective study to validate the functional assessment of cancer therapy (FACT) for epidermal growth factor receptor inhibitor (EGFRI)-induced dermatologic toxicities FACT-EGFRI 18 questionnaire: SWOG S1013","volume":"4","author":"Wong","year":"2020","journal-title":"J\u00a0Patient Rep Outcomes"},{"issue":"3","key":"10.1016\/j.esmoop.2024.103628_bib19","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1111\/j.1365-2230.1994.tb01167.x","article-title":"Dermatology Life Quality Index (DLQI) - a simple practical measure for routine clinical use","volume":"19","author":"Finlay","year":"1994","journal-title":"Clin Exp Dermatol"},{"issue":"2","key":"10.1016\/j.esmoop.2024.103628_bib20","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1177\/120347540100500202","article-title":"Measurement properties of Skindex-16: a brief quality-of-life measure for patients with skin diseases","volume":"5","author":"Chren","year":"2001","journal-title":"J\u00a0Cutan Med Surg"},{"issue":"11","key":"10.1016\/j.esmoop.2024.103628_bib21","doi-asserted-by":"crossref","first-page":"2604","DOI":"10.3390\/cancers13112604","article-title":"Quality of life in vulnerable older patients with metastatic colorectal cancer receiving palliative chemotherapy-the randomized NORDIC9-study","volume":"13","author":"Liposits","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"2","key":"10.1016\/j.esmoop.2024.103628_bib22","doi-asserted-by":"crossref","first-page":"e49","DOI":"10.1016\/j.clcc.2021.09.001","article-title":"Health-related quality of life analysis in metastatic colorectal cancer patients treated by second-line chemotherapy, associated with either cetuximab or bevacizumab: the PRODIGE 18 randomized phase II study","volume":"21","author":"Bertaut","year":"2022","journal-title":"Clin Colorectal Cancer"},{"issue":"2","key":"10.1016\/j.esmoop.2024.103628_bib23","doi-asserted-by":"crossref","first-page":"e29","DOI":"10.1016\/j.clcc.2016.07.017","article-title":"Quality of life analysis in patients with RAS wild-type metastatic colorectal cancer treated with first-line cetuximab plus chemotherapy","volume":"16","author":"Yamaguchi","year":"2017","journal-title":"Clin Colorectal Cancer"},{"key":"10.1016\/j.esmoop.2024.103628_bib24","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.ejca.2020.11.029","article-title":"Quality of life in rectal cancer patients with or without oxaliplatin in the randomised CAO\/ARO\/AIO-04 phase 3 trial","volume":"144","author":"Kosmala","year":"2021","journal-title":"Eur J Cancer"},{"issue":"6","key":"10.1016\/j.esmoop.2024.103628_bib25","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1038\/sj.jid.5700740","article-title":"Quality-of-life outcomes of treatments for cutaneous basal cell carcinoma and squamous cell carcinoma","volume":"127","author":"Chren","year":"2007","journal-title":"J\u00a0Invest Dermatol"},{"issue":"1","key":"10.1016\/j.esmoop.2024.103628_bib26","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1159\/000365390","article-title":"Determining the minimal clinically important difference and responsiveness of the Dermatology Life Quality Index (DLQI): further data","volume":"230","author":"Basra","year":"2015","journal-title":"Dermatology"},{"issue":"24","key":"10.1016\/j.esmoop.2024.103628_bib27","doi-asserted-by":"crossref","first-page":"9419","DOI":"10.1002\/cam4.3564","article-title":"Disagreement between patient- and physician-reported outcomes on symptomatic adverse events as poor prognosis in patients treated with first-line cetuximab plus chemotherapy for unresectable metastatic colorectal cancer: results of Phase II QUACK trial","volume":"9","author":"Ooki","year":"2020","journal-title":"Cancer Med"},{"issue":"1","key":"10.1016\/j.esmoop.2024.103628_bib28","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.annonc.2019.10.001","article-title":"Relation of cetuximab-induced skin toxicity and early tumor shrinkage in metastatic colorectal cancer patients: results of the randomized phase 3 trial FIRE-3 (AIO KRK0306)","volume":"31","author":"Holch","year":"2020","journal-title":"Ann Oncol"},{"issue":"4","key":"10.1016\/j.esmoop.2024.103628_bib29","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1056\/NEJMoa033025","article-title":"Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer","volume":"351","author":"Cunningham","year":"2004","journal-title":"N\u00a0Engl J Med"},{"issue":"7","key":"10.1016\/j.esmoop.2024.103628_bib30","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1200\/JCO.2004.10.182","article-title":"Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor","volume":"22","author":"Saltz","year":"2004","journal-title":"J\u00a0Clin Oncol"},{"issue":"30","key":"10.1016\/j.esmoop.2024.103628_bib31","doi-asserted-by":"crossref","first-page":"4914","DOI":"10.1200\/JCO.2006.06.7595","article-title":"Multicenter phase II and translational study of cetuximab in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin, and fluoropyrimidines","volume":"24","author":"Lenz","year":"2006","journal-title":"J\u00a0Clin Oncol"},{"issue":"20","key":"10.1016\/j.esmoop.2024.103628_bib32","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1056\/NEJMoa071834","article-title":"Cetuximab for the treatment of colorectal cancer","volume":"357","author":"Jonker","year":"2007","journal-title":"N\u00a0Engl J Med"},{"issue":"7","key":"10.1016\/j.esmoop.2024.103628_bib33","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1200\/JCO.2014.59.4812","article-title":"Fluorouracil, leucovorin, and irinotecan plus cetuximab treatment and RAS mutations in colorectal cancer","volume":"33","author":"Van Cutsem","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"issue":"1","key":"10.1016\/j.esmoop.2024.103628_bib34","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1093\/annonc\/mdm399","article-title":"An open-label, single-arm study assessing safety and efficacy of panitumumab in patients with metastatic colorectal cancer refractory to standard chemotherapy","volume":"19","author":"Van Cutsem","year":"2008","journal-title":"Ann Oncol"},{"issue":"5","key":"10.1016\/j.esmoop.2024.103628_bib35","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1002\/cncr.22915","article-title":"Panitumumab monotherapy in patients with previously treated metastatic colorectal cancer","volume":"110","author":"Hecht","year":"2007","journal-title":"Cancer"},{"issue":"12","key":"10.1016\/j.esmoop.2024.103628_bib36","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1634\/theoncologist.2011-0163","article-title":"Toxicity as a biomarker of efficacy of molecular targeted therapies: focus on EGFR and VEGF inhibiting anticancer drugs","volume":"16","author":"Dienstmann","year":"2011","journal-title":"Oncologist"},{"issue":"8","key":"10.1016\/j.esmoop.2024.103628_bib37","doi-asserted-by":"crossref","first-page":"3669","DOI":"10.1007\/s00520-016-3297-9","article-title":"The association between clinician-based common terminology criteria for adverse events (CTCAE) and patient-reported outcomes (PRO): a systematic review","volume":"24","author":"Atkinson","year":"2016","journal-title":"Support Care Cancer"},{"issue":"9","key":"10.1016\/j.esmoop.2024.103628_bib38","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/dju244","article-title":"Development of the National Cancer Institute's patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE)","volume":"106","author":"Basch","year":"2014","journal-title":"J\u00a0Natl Cancer Inst"}],"container-title":["ESMO Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702924013978?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702924013978?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,10,5]],"date-time":"2024-10-05T00:07:51Z","timestamp":1728086871000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2059702924013978"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":38,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["S2059702924013978"],"URL":"https:\/\/doi.org\/10.1016\/j.esmoop.2024.103628","relation":{},"ISSN":["2059-7029"],"issn-type":[{"value":"2059-7029","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Dermatology-related quality-of-life outcomes in patients with RAS wild-type metastatic colorectal cancer treated with fluorouracil and folinic acid with or without panitumumab (Pmab) maintenance after FOLFOX\u00a0+ Pmab induction: a prespecified secondary analysis of the phase II randomized PanaMa (AIO KRK 0212) trial","name":"articletitle","label":"Article Title"},{"value":"ESMO Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.esmoop.2024.103628","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}],"article-number":"103628"}}